Profile data is unavailable for this security.
About the company
Verici Dx plc is a developer of advanced clinical diagnostics for organ transplants. The Company develops a suite of tests forming a kidney transplant platform for personalized patients and organ response risk to assist clinicians in medical management for improved patient outcomes. The principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The Company's kidney transplant assays use sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The Company develops tests to understand how a patient is responding to organ transplants. Its products include Clarava, Tuteva and Protega. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including subclinical rejection. Protega is a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure.
- Revenue in GBP (TTM)1.40m
- Net income in GBP-5.58m
- Incorporated2020
- Employees15.00
- LocationVerici DX PLC393 Nichol Mill Lane, Suite 200FRANKLIN 37067United StatesUSA
- Websitehttps://vericidx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genincode PLC | 2.91m | -4.97m | 3.16m | 36.00 | -- | 1.19 | -- | 1.08 | -0.0232 | -0.0232 | 0.0137 | 0.0093 | 0.6562 | 15.74 | 2.87 | 80,944.45 | -111.87 | -- | -164.53 | -- | 53.02 | -- | -170.49 | -- | 2.73 | -10.96 | 0.0669 | -- | 25.05 | -- | 36.80 | -- | -- | -- |
| Surgical Innovations Group Plc | 11.92m | -1.44m | 4.20m | 88.00 | -- | 0.4903 | -- | 0.3523 | -0.0015 | -0.0015 | 0.0128 | 0.0092 | 0.9314 | 2.91 | 4.72 | 135,397.70 | -11.22 | -7.76 | -14.17 | -9.60 | 27.89 | 29.97 | -12.04 | -11.66 | 0.9524 | 8.46 | 0.0987 | -- | -0.5743 | 2.16 | -281.73 | -- | -8.28 | -- |
| Cambridge Nutritional Sciences PLC | 8.06m | 1.37m | 4.76m | 84.00 | 3.50 | 0.4305 | 2.38 | 0.5905 | 0.0057 | 0.0057 | 0.0338 | 0.0465 | 0.6153 | 3.59 | 3.57 | 95,940.48 | 10.42 | -3.22 | 11.69 | -3.67 | 66.44 | 58.85 | 16.94 | -7.21 | 3.79 | -- | 0.021 | -- | -14.77 | -3.23 | 577.44 | -- | -29.24 | -- |
| Feedback plc | 885.62k | -7.32m | 4.89m | 28.00 | -- | 0.7925 | -- | 5.52 | -0.2618 | -0.2618 | 0.0309 | 0.1407 | 0.1174 | -- | 9.83 | 31,629.29 | -96.97 | -38.54 | -105.98 | -41.65 | 87.92 | 90.05 | -826.25 | -435.27 | -- | -- | 0.00 | -- | -25.05 | 14.50 | -121.85 | -- | -1.14 | -- |
| Proteome Sciences plc | 4.53m | -3.33m | 6.23m | 36.00 | -- | -- | -- | 1.38 | -0.0113 | -0.0113 | 0.0153 | -0.0291 | 0.5087 | 5.92 | 5.75 | 125,750.00 | -37.44 | -8.02 | -- | -- | 17.43 | 45.80 | -73.60 | -15.07 | 0.0774 | -2.51 | 2.26 | -- | -2.80 | 0.9731 | -39.42 | -- | 31.03 | -- |
| Rua Life Sciences PLC | 5.17m | -850.00k | 8.38m | 33.00 | -- | 1.17 | -- | 1.62 | -0.0137 | -0.0137 | 0.0832 | 0.1151 | 0.5459 | 1.18 | 6.23 | -- | -9.18 | -- | -10.42 | -- | 77.10 | -- | -16.82 | -- | 3.87 | -- | 0.0995 | -- | -- | -- | -- | -- | -- | -- |
| Verici DX PLC | 1.40m | -5.58m | 10.44m | 15.00 | -- | 0.9197 | -- | 7.45 | -0.023 | -0.023 | 0.0058 | 0.0075 | 0.2298 | -- | 1.67 | 77,916.49 | -91.48 | -- | -119.40 | -- | 81.60 | -- | -398.12 | -- | -- | -- | 0.102 | -- | 229.62 | -- | 32.75 | -- | -- | -- |
| Genedrive PLC | 954.00k | -5.23m | 11.33m | 43.00 | -- | 4.78 | -- | 11.87 | -0.0093 | -0.0093 | 0.0017 | 0.0023 | 0.1984 | -- | 1.80 | 22,186.05 | -108.81 | -77.52 | -153.92 | -106.30 | -- | -- | -548.32 | -1,016.12 | 1.64 | -- | 0.00 | -- | 90.42 | -2.07 | 26.06 | -- | -10.48 | -- |
| Cellbxhealth PLC | 2.62m | -15.78m | 11.96m | 119.00 | -- | 0.2897 | -- | 4.56 | -0.0489 | -0.0489 | 0.0081 | 0.0362 | 0.1028 | 0.5939 | 1.46 | 22,050.42 | -61.80 | -41.90 | -72.78 | -46.81 | 62.27 | 18.55 | -601.37 | -1,051.13 | 2.63 | -470.57 | 0.2387 | -- | 30.92 | -- | 29.34 | -- | -- | -- |
| Abingdon Health PLC | 8.43m | -3.42m | 15.06m | 121.00 | -- | 2.19 | -- | 1.79 | -0.0176 | -0.0176 | 0.0435 | 0.0274 | 1.17 | 9.71 | 3.87 | 69,661.16 | -47.42 | -54.04 | -70.70 | -85.91 | 44.32 | 30.37 | -40.51 | -110.07 | 1.58 | -- | 0.1625 | -- | 37.39 | 9.99 | -168.69 | -- | -26.92 | -- |
| Inspiration Healthcare Group PLC | 45.20m | -11.44m | 15.47m | 214.00 | -- | 0.9449 | -- | 0.3422 | -0.1275 | -0.1275 | 0.5038 | 0.1826 | 1.03 | 2.00 | 5.91 | 211,215.00 | -25.96 | -6.05 | -33.03 | -7.45 | 44.39 | 46.62 | -25.32 | -7.01 | 1.11 | 2.42 | 0.441 | -- | 1.65 | 16.56 | -148.04 | -- | 39.05 | -- |
| Renalytix PLC | 2.20m | -14.96m | 24.47m | 45.00 | -- | -- | -- | 11.13 | -0.0596 | -0.0596 | 0.008 | -0.0155 | 0.4547 | 7.64 | 4.54 | -- | -309.18 | -83.70 | -- | -107.25 | 40.00 | 28.27 | -680.00 | -1,519.31 | 1.17 | -24.57 | 6.38 | -- | 31.06 | -- | 55.14 | -- | -- | -- |
| Aptamer Group PLC | 1.20m | -2.42m | 25.62m | 31.00 | -- | 13.69 | -- | 21.30 | -0.0014 | -0.0014 | 0.0007 | 0.0007 | 0.4294 | 6.27 | 4.35 | 38,806.45 | -86.53 | -- | -154.00 | -- | 48.13 | -- | -201.50 | -- | 1.48 | -84.63 | 0.2622 | -- | 39.88 | -- | 18.05 | -- | -- | -- |
Data as of Feb 11 2026. Currency figures normalised to Verici DX PLC's reporting currency: UK Pound GBX
42.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Harwood Capital LLPas of 30 Sep 2025 | 193.07m | 12.76% |
| Canaccord Genuity Wealth Ltd.as of 30 Jul 2025 | 157.13m | 10.38% |
| Unicorn Asset Management Ltd.as of 30 Jul 2025 | 119.62m | 7.90% |
| UBS Asset Management (UK) Ltd.as of 30 Jul 2025 | 118.31m | 7.82% |
| Octopus Investments Ltd.as of 24 Jul 2025 | 21.48m | 1.42% |
| Hargreaves Lansdown Asset Management Ltd.as of 31 Mar 2025 | 17.36m | 1.15% |
| Rathbones Investment Management Ltd.as of 31 Mar 2025 | 9.25m | 0.61% |
| Oberon Investments Ltd. (GB Investment Management)as of 30 Jun 2025 | 323.13k | 0.02% |
| Foresight Group LLP (Investment Management)as of 30 Sep 2025 | 148.10k | 0.01% |
More ▼
Data from 30 Sep 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
